Subcutaneous Administration of Teplizumab in Adults With Type 1 Diabetes
Status:
Terminated
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety, tolerability, pharmacodynamics (PD) and
pharmacokinetics (PK) of subcutaneously administered teplizumab in adults with relatively
recent onset T1DM, greater than 12 weeks and less than 52 weeks of presentation of first
signs and symptoms of disease to a physician prior to randomization.